Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ALSFRS-R.

Paul H Gordon1, Robert G Miller, Dan H Moore

  • 1Eleanor and Lou Gehrig MDA/ALS Research Center, Neurological Institute, New York, NY 10032, USA. pgordon@neuro.columbia.edu

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
|October 30, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduction of daily-use parabens and phthalates reverses accumulation of cancer-associated phenotypes within disease-free breast tissue of study subjects.

Chemosphere·2023
Same author

Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses.

Muscle & nerve·2022
Same author

A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis.

Muscle & nerve·2021
Same author

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.

Neurology·2019
Same author

A Ternary Mixture of Common Chemicals Perturbs Benign Human Breast Epithelial Cells More Than the Same Chemicals Do Individually.

Toxicological sciences : an official journal of the Society of Toxicology·2018
Same author

Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial.

Muscle & nerve·2018
Same journal

Dementia of frontal lobe type in Kennedy's disease.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
Same journal

Venous thrombosis in an ALS population over four years.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
Same journal

Spirometer-dependence of vital capacity in ALS: validation of a portable device in 52 patients.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
Same journal

A rare Cu/Zn superoxide dismutase mutation causing familial amyotrophic lateral sclerosis with variable age of onset and incomplete penetrance in China.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
Same journal

Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
Same journal

Psychopathology in amyotrophic lateral sclerosis: a preliminary study with 27 ALS patients.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
See all related articles

The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) is a valuable tool for clinical trials. It effectively measures global function, correlates with survival, and simplifies trial administration.

Area of Science:

  • Neurology
  • Clinical Trials
  • Biostatistics

Background:

  • Amyotrophic Lateral Sclerosis (ALS) presents challenges for clinical trial outcome measures.
  • Existing measures may not fully capture global functional decline in ALS patients.

Purpose of the Study:

  • To evaluate the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) as a primary outcome measure in ALS clinical trials.
  • To highlight the advantages of the ALSFRS-R over other standard outcome measures.

Main Methods:

  • The study focuses on the validated properties of the ALSFRS-R.
  • Analysis of its ease of administration, dropout minimization, and cost-effectiveness.
  • Assessment of its correlation with patient survival and global function.

Related Experiment Videos

Main Results:

  • The ALSFRS-R is a validated and reliable measure for ALS clinical trials.
  • It offers practical benefits including reduced dropout rates and lower costs.
  • The ALSFRS-R demonstrates a correlation with patient survival and assesses global function.

Conclusions:

  • The ALSFRS-R is a highly suitable primary outcome measure for ALS clinical trials.
  • Its comprehensive assessment of global function and practical advantages make it superior to other measures.
  • Utilizing the ALSFRS-R can enhance the efficiency and effectiveness of ALS therapeutic development.